<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="78795">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01719146</url>
  </required_header>
  <id_info>
    <org_study_id>R01 DK093832-01A1</org_study_id>
    <secondary_id>R01DK093832</secondary_id>
    <nct_id>NCT01719146</nct_id>
  </id_info>
  <brief_title>Prospective Observational Study of Erythropoietin-Iron Interaction in Anemia of Renal Disease</brief_title>
  <official_title>Computational Approach to Personalized Anemia Management</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Louisville</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Louisville</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to prospectively collect data on doses of Erythropoietic
      Stimulating Agents and Intravenous Iron, and the markers of erythropoietic activity and iron
      status. These data will be used to derive mathematical models which will subsequently guide
      dosing of both agents, such that a desired therapeutic outcome is achieved in every patient,
      while minimizing patient exposure to both agents.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Data will be collected from 120 subjects undergoing hemodialysis treatment at 3 clinical
      sites across United States (40 per site).5.5 mL blood specimen will be drawn during midweek
      treatment (Wed/Thu) to measure:

      Hemoglobin Concentration Hematocrit Red Blood Cell Count Platelet Count Reticulocyte
      Percentage Reticulocyte Hemoglobin Mean Cellular Hemoglobin Mean Cellular Hemoglobin
      Concentration Mean Cell Volume Red Cell Volume Distribution Width Mean Platelet Volume Serum
      Iron Serum Ferritin Transferrin Saturation Hepcidin Soluble Transferrin Receptor

      Weekly ESA and Iron dose delivered will also be recorded.

      From these data:

        1. a mathematical model will be established to find biomarkers most descriptive with
           respect to erythropoiesis-iron synergy,

        2. a mathematical model will be established to correlate iron dose with iron markers.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">August 2016</completion_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Hemoglobin Concentration (g/dL)</measure>
    <time_frame>52 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reticulocyte Percentage (%)</measure>
    <time_frame>52 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reticulocyte Hemoglobin Equivalent, RetHe (pg)</measure>
    <time_frame>52 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Transferrin Saturation (%)</measure>
    <time_frame>52 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Serum Ferritin (ng/mL)</measure>
    <time_frame>52 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Anemia of End Stage Renal Disease</condition>
  <arm_group>
    <arm_group_label>UofL Subjects</arm_group_label>
    <description>Subjects undergoing Specimen Collection at University Kidney Center, University of Louisville, Louisville, KY</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Duke Subjects</arm_group_label>
    <description>Subjects undergoing Specimen Collection at Duke University, Durham, NC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>WNERTA Subjects</arm_group_label>
    <description>Subject undergoing Specimen Collection at Western New England Renal and Transplant Associates, Springfield, MA</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Specimen collection</intervention_name>
    <description>At the beginning of each midweek hemodialysis session, a blood specimen (4 mL) will be drawn from the study subject. Out of this specimen a 1 mL serum sample will be frozen and stored. A 3 mL blood sample will be shipped overnight to WNERTA for laboratory testing.</description>
    <arm_group_label>UofL Subjects</arm_group_label>
    <arm_group_label>Duke Subjects</arm_group_label>
    <arm_group_label>WNERTA Subjects</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood, serum will be extracted and frozen for further analysis. Serum will be retained for
      up to 60 days.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        End Stage Renal Disease Patients undergoing hemodialysis treatments at:

          1. University Kidney Center, Louisville, KY

          2. Duke University, Durham, NC

          3. WNERTA, Springfield, MA
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  receiving or expected to receive ESA

        Exclusion Criteria:

          -  life expectancy less than 12 months

          -  frequent (once or more per month w/in last 6 months) uncontrolled blood loss

          -  frequent (once or more per month w/in last 6 months) hospitalization

          -  frequent (once or more per month w/in last 6 months) access complications
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adam E Gaweda, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Louisville</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Louisville, University Kidney Center</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Moore</last_name>
      <phone>502-852-2290</phone>
      <email>amdalt01@exchange.louisville.edu</email>
    </contact>
    <contact_backup>
      <last_name>Rachael Anderson</last_name>
      <phone>502-852-2290</phone>
      <email>rnande03@louisville.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Adam E Gaweda, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>George R Aronoff, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Western New England Renal and Transplant Associates</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael J Germain, M.D.</last_name>
      <phone>413-794-2604</phone>
      <email>Michael.Germain@baystatehealth.org</email>
    </contact>
    <investigator>
      <last_name>Michael J Germain, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick H Pun, MD</last_name>
      <phone>919-660-6865</phone>
      <email>patrick.pun@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Patrick Pun, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <lastchanged_date>January 25, 2013</lastchanged_date>
  <firstreceived_date>October 29, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anemia</keyword>
  <keyword>Chronic Kidney Disease</keyword>
  <keyword>Erythropoiesis Stimulating Agents</keyword>
  <keyword>Erythropoietin</keyword>
  <keyword>Iron</keyword>
  <keyword>Iron Deficiency</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Epoetin Alfa</mesh_term>
    <mesh_term>Hematinics</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
